The CDC Domestic Mpox Response — United States, 2022–2023

Abstract

other federal, state, and local partners. CDC quickly adapted surveillance systems, diagnostic tests, vaccines, therapeutics, grants, and communication systems originally developed for U.S. smallpox preparedness and other infectious diseases to t the unique needs of the outbreak. In 1 year, more than 30,000 U.S. mpox cases were reported, more than 140,000 specimens were tested, >1.2 million doses of vaccine were administered, and more than 6,900 patients were treated with tecovirimat, an antiviral medication with activity against orthopoxviruses such as Variola virus and Monkeypox virus. Non-Hispanic Black (Black) and Hispanic or Latino (Hispanic) persons represented 33% and 31% of mpox 1 2 1 1 3 4 5 6 1 7 8 9 1 3 10 1 4 3 1 8 11 Summary What is already known about this topic? After being detected in May 2022, U.S. monkeypox (mpox) cases increased rapidly, peaking in August. Infection was primarily spread by sexual contact among gay, bisexual, and other men who have sex with men. What is added by this report? Rapid adaptation of smallpox preparedness systems and tools, and prioritized communication expertise from HIV prevention programs, were leveraged to reach communities at risk. In 1 year, more than 30,000 cases were reported and >1 million JYNNEOS vaccine doses were administered. Black and Hispanic persons represented 33% and 31% of cases, respectively; 87% of 42 fatal cases occurred in Black persons. What are the implications for public health practice? The U.S. risk for future mpox outbreaks remains. Ongoing surveillance, vaccination, and communication are important prevention tools, especially for Black and Hispanic persons in groups at risk.